全球过敏疫苗市场－按过敏类型、疫苗类型、应用、最终用户、地区和竞争格局分類的行业规模、份额、趋势、机会和预测（2021-2031年）

全球过敏疫苗市场预计将从 2025 年的 14.2 亿美元成长到 2031 年的 22.9 亿美元，复合年增长率为 8.29%。

这些疫苗，技术上称为过敏原免疫疗法，其作用机制是透过向患者註射递增剂量的特定过敏原，以促进长期免疫耐受性。推动这一市场发展的关键因素包括全球慢性过敏性呼吸系统疾病的盛行率上升，以及气候变迁等环境变迁导致花粉季延长、过敏原暴露增加。根据美国气喘和过敏基金会2024年的数据，美国有超过1亿人患有过敏性疾病，这表明迫切需要针对这些疾病根本原因而非仅缓解症状的缓解疾病疗法。

儘管市场需求强劲，但患者依从性和有效治疗所需的长期疗程在市场中面临严峻挑战。需要多年治疗，且经常涉及频繁的皮下注射或每日舌下给药，这通常会导致较高的停药率。这种长期依从性难题阻碍了免疫疗法的广泛应用，并限制了其潜在的产生收入。

市场驱动因素

全球慢性过敏性呼吸道疾病和食物相关疾病发生率的不断上升是推动全球过敏疫苗市场发展的主要因素。快速的都市化和日益严重的环境污染导致过敏率不断攀升，迫切需要超越单纯症状管理的长期免疫疗法干预措施。这种成长趋势在成年人中尤其显着，使他们成为新型脱敏策略的重要目标人口。例如，根据英国食品标准局2024年5月发布的《成人食物过敏盛行率报告》，约6%的英国成年人患有临床确诊的食物过敏，为新兴候选疫苗提供了庞大的潜在市场。

同时，便利的舌下免疫疗法（SLIT）製剂获得越来越多的监管核准，正在改变治疗格局，有效解决了传统皮下注射通用的依从性问题。这些非侵入性、居家服用的药片正日益受到患者和医疗服务提供者的青睐，减轻了患者频繁就诊的负担，并提高了治疗完成率。这种给药方式的转变正在推动实际的商业性成功。 ALK-Abello公司报告称，其过敏免疫疗法片剂在2024年2月的该地货币销售额增长了11%，这证实了患者对便利治疗方案的接受度正在加速提高。儿童需求进一步推动了这一趋势。伦敦帝国学院指出，2024年学龄前儿童食物过敏的盛行率将达到4%，这表明所有年龄层对有效治疗方法的需求仍然存在。

市场挑战

全球过敏疫苗市场成长的主要障碍在于难以确保患者持续坚持严格的长期治疗方案，而这对于确保疗效至关重要。过敏原免疫疗法通常需要3-5年的长期治疗，包括频繁的皮下注射或每日舌下含服。这种长期治疗对患者来说负担极重，会导致“治疗疲劳”，并常常导致患者在建立长期耐受性之前就停止治疗。因此，高治疗中断率直接减少了生产商的持续收入，并限制了市场的整体扩张，因为治疗的全部价值和经济回报只有在完成整个疗程后才能实现。

近期临床数据凸显了病患流失的严重性。 2024年，美国过敏、气喘和免疫学会（ACAAI）在其年度科学会议上发表了一项纵向研究，结果显示，五年内有42.8%的患者停止了免疫疗法。此类统计数据凸显了患者治疗体系的脆弱性。当近一半的患者无法完成整个疗程时，潜在的患者群体实际上就减少了。这种低依从性不仅直接导致收入下降，也使得医疗服务提供者不愿开立此类治疗方法，他们担心长期投入的时间和资源无法带来预期的临床疗效。

市场趋势

类病毒颗粒（VLP）疫苗平台的进步正在重新定义过敏治疗，其提供的短期免疫调节疗法克服了传统萃取物疗法在安全性和疗程方面的限制。透过利用重组技术增强免疫识别，这些候选疫苗有望显着缩短长达数年的治疗通讯协定。近期临床结果也支持了这项进展。 2024年12月，Allergy Therapeutics公司公布了PROTECT试验的中期数据，结果显示，接受该公司VLP花生候选疫苗治疗的患者在皮肤点刺试验后，风团面积缩小了48%，而安慰剂组仅缩小了8%。这凸显了该平台在快速脱敏和提高治疗维持率方面的潜力。

同时，经皮免疫疗法贴片的研发正在改变整个产业，尤其是在需要非侵入性治疗的儿童食物过敏领域。这些贴片利用皮肤自身的免疫系统诱导耐受，最大限度地降低了口服和注射给药途径相关的过敏反应风险。商业化进程正在加速，DBV Technologies公司于2024年10月宣布，其关键性VITESSE III期临床试验已招募了654名受试者。这项进展凸显了产业向基于皮肤的给药系统策略转型，以满足食物过敏领域巨大的市场需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球过敏疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依过敏类型（过敏性气喘、猫毛过敏、草花粉过敏、花生过敏、季节性过敏性鼻炎、树木花粉过敏）
  • 依疫苗类型分类（猫过敏疫苗、家尘螨过敏疫苗、注射型MPL过敏疫苗、花生过敏疫苗、豚草过敏免疫疗法疫苗）
  • 依应用领域（爱滋病、肿瘤、呼吸系统）
  • 按最终使用者（居家医疗、医院、专科诊所等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美过敏疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲过敏疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区过敏疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲过敏疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲过敏疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球过敏疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Stallergenes Greer PLC
• Allergy Therapeutics PLC
• HAL Allergy BV
• Jubilant HollisterStier Allergy
• Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• Dermapharm AG
• Merck KGaA
• Aimmune Therapeutics Inc.
• Biomay AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Allergy Vaccine Market is projected to expand from USD 1.42 Billion in 2025 to USD 2.29 Billion by 2031, reflecting a CAGR of 8.29%. These vaccines, technically known as allergen immunotherapy, function by administering incrementally increasing doses of a specific allergen to the patient to foster long-term immune tolerance. The primary factors driving this market include the rising global prevalence of chronic allergic respiratory diseases and environmental changes, such as climate shifts that extend pollen seasons and heighten allergen exposure. Data from the Asthma and Allergy Foundation of America in 2024 indicates that allergic conditions affect over 100 million people in the United States, highlighting a critical need for disease-modifying treatments that target the root causes of these pathologies rather than simply providing temporary symptom relief.

Despite strong demand, the market faces significant hurdles regarding patient compliance and the extended duration required for effective treatment. The necessity for multi-year regimens, which involve either frequent subcutaneous injections or daily sublingual administration, often results in high discontinuation rates. This difficulty in maintaining long-term commitment hampers the broader adoption of these immunotherapeutic solutions and restricts their potential revenue generation.

Market Driver

The escalating global incidence of chronic allergic respiratory and food-related disorders serves as the primary force propelling the Global Allergy Vaccine Market. Rapid urbanization and rising environmental pollution are increasing sensitization rates, creating an urgent requirement for long-term immunotherapeutic interventions beyond mere symptom management. This surge is particularly noticeable among adults, establishing a significant demographic for novel desensitization strategies. For instance, the Food Standards Agency's May 2024 report on adult food allergy prevalence revealed that approximately 6% of the adult population in the United Kingdom now has a clinically confirmed food allergy, representing a vastly expanded addressable market for emerging vaccine candidates.

Simultaneously, the increasing regulatory approval of convenient Sublingual Immunotherapy (SLIT) formulations is transforming the treatment landscape by addressing the adherence challenges common with traditional subcutaneous injections. Both patients and healthcare providers are favoring these non-invasive, home-administered tablets, as they reduce the burden of frequent clinic visits and improve therapy completion rates. This shift in delivery preference is driving tangible commercial success; ALK-Abello reported in February 2024 that sales of its allergy immunotherapy tablets grew by 11% in local currencies, underscoring the accelerated adoption of these patient-friendly options. This demand is further reinforced by pediatric needs, with Imperial College London noting in 2024 that food allergy prevalence in preschool-aged children has reached 4%, signaling a sustained need for effective therapies across all age groups.

Market Challenge

A major obstacle hindering the growth of the Global Allergy Vaccine Market is the difficulty in ensuring patient adherence to the rigorous and lengthy treatment regimens necessary for efficacy. Allergen immunotherapy requires a multi-year commitment, typically lasting three to five years, involving either frequent subcutaneous injections or daily sublingual doses. This prolonged duration imposes a significant burden on patients, often leading to "treatment fatigue," where individuals abandon therapy before long-term tolerance is achieved. Consequently, high discontinuation rates directly reduce recurring revenue streams for manufacturers and limit overall market expansion, as the full therapeutic value and financial return are only realized upon course completion.

The severity of this attrition is highlighted by recent clinical data. In 2024, the American College of Allergy, Asthma & Immunology (ACAAI) presented a longitudinal study at their Annual Scientific Meeting revealing that 42.8% of patients discontinued immunotherapy over a five-year period. Such statistics emphasize the fragility of the patient pipeline; when nearly half of initiated patients fail to complete the full regimen, the market's potential addressable audience effectively shrinks. This pattern of non-compliance not only diminishes direct sales but also causes hesitation among healthcare providers to prescribe these therapies, fearing that the long-term investment of time and resources will not yield the desired clinical outcomes.

Market Trends

Advancements in Virus-Like Particle (VLP) Vaccine Platforms are redefining allergy treatment by providing short-course immunomodulation that addresses the safety and duration limitations of traditional extracts. These candidates utilize recombinant technology to improve immune recognition, potentially condensing multi-year protocols into much shorter regimens. This progress is supported by recent clinical results; in December 2024, Allergy Therapeutics reported positive interim data from the PROTECT Trial, showing that patients treated with their VLP Peanut candidate experienced a 48% reduction in wheal size after skin-prick testing, compared to an 8% reduction in the placebo group, underscoring the platform's potential for rapid desensitization and better adherence.

Concurrently, the development of Epicutaneous Immunotherapy Patches is reshaping the sector, particularly for pediatric food allergies requiring non-invasive solutions. By leveraging the skin's immune system to induce tolerance, these patches minimize the anaphylactic risks associated with oral or injectable routes. Commercialization efforts are intensifying; DBV Technologies announced in October 2024 that it had enrolled 654 subjects in its pivotal VITESSE Phase 3 trial. This development confirms the industry's strategic pivot toward skin-based delivery systems to capture the substantial demand within the food allergy segment.

Key Market Players

• Stallergenes Greer PLC
• Allergy Therapeutics PLC
• HAL Allergy BV
• Jubilant HollisterStier Allergy
• Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• Dermapharm AG
• Merck KGaA
• Aimmune Therapeutics Inc.
• Biomay AG

Report Scope

In this report, the Global Allergy Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Vaccine Market, By Allergy Type

• Allergic Asthma
• Cat Dander Allergy
• Grass Pollen Hypersensitivity
• Peanut Hypersensitivity
• Seasonal Allergic Rhinitis
• Tree Pollen Hypersensitivity

Allergy Vaccine Market, By Vaccine Type

• Cat Allergy Vaccine
• House Dust Mite Allergy Vaccine
• Injectable MPL Allergy Vaccine
• Peanut Allergy Vaccine
• Ragweed Allergy Immunotherapy Vaccine

Allergy Vaccine Market, By Application

• HIV
• Oncology
• Respiratory

Allergy Vaccine Market, By End User

• Homecare
• Hospitals
• Specialty Clinics
• Others

Allergy Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Vaccine Market.

Available Customizations:

Global Allergy Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 5.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 5.2.3. By Application (HIV, Oncology, Respiratory)
  • 5.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Allergy Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Allergy Type
  • 6.2.2. By Vaccine Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Allergy Type
      • 6.3.1.2.2. By Vaccine Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Allergy Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Allergy Type
      • 6.3.2.2.2. By Vaccine Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Allergy Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Allergy Type
      • 6.3.3.2.2. By Vaccine Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Allergy Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Allergy Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Allergy Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Allergy Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Allergy Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Allergy Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Allergy Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Allergy Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Allergy Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Allergy Type
      • 7.3.4.2.2. By Vaccine Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Allergy Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Allergy Type
      • 7.3.5.2.2. By Vaccine Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Allergy Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Allergy Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Allergy Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Allergy Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Allergy Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Allergy Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Allergy Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Allergy Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Allergy Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Allergy Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Allergy Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Allergy Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Allergy Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Allergy Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Allergy Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Allergy Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Allergy Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Allergy Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Allergy Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Allergy Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Allergy Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Allergy Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Allergy Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Allergy Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Allergy Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Allergy Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Allergy Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Allergy Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Allergy Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Stallergenes Greer PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allergy Therapeutics PLC
• 15.3. HAL Allergy BV
• 15.4. Jubilant HollisterStier Allergy
• 15.5. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• 15.6. Dermapharm AG
• 15.7. Merck KGaA
• 15.8. Aimmune Therapeutics Inc.
• 15.9. Biomay AG

16. Strategic Recommendations

17. About Us & Disclaimer